These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 38515791)

  • 21. Cigarette Smoke Containing Acrolein Contributes to Cisplatin Resistance in Human Bladder Cancers through the Regulation of HER2 Pathway or FGFR3 Pathway.
    Hong JH; Tong ZJ; Wei TE; Lu YC; Huang CY; Huang CY; Chiang CH; Jaw FS; Cheng HW; Wang HT
    Mol Cancer Ther; 2022 Jun; 21(6):1010-1019. PubMed ID: 35312783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LncRNA-MALAT1 mediates cisplatin resistance via miR-101-3p/VEGF-C pathway in bladder cancer.
    Liu P; Li X; Cui Y; Chen J; Li C; Li Q; Li H; Zhang X; Zu X
    Acta Biochim Biophys Sin (Shanghai); 2019 Nov; 51(11):1148-1157. PubMed ID: 31650173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel circular RNA (hsa_circRNA_102336), a plausible biomarker, promotes the tumorigenesis by sponging miR-515-5p in human bladder cancer.
    Gong P; Xu R; Zhuang Q; He X
    Biomed Pharmacother; 2020 Jun; 126():110059. PubMed ID: 32208321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study.
    Grossmann NC; Rajwa P; Quhal F; König F; Mostafaei H; Laukhtina E; Mori K; Katayama S; Motlagh RS; Fankhauser CD; Mattei A; Moschini M; Chlosta P; van Rhijn BWG; Teoh JYC; Compérat E; Babjuk M; Abufaraj M; Karakiewicz PI; Shariat SF; Pradere B
    Eur Urol Open Sci; 2022 May; 39():14-21. PubMed ID: 35528782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LINC00857 expression predicts and mediates the response to platinum-based chemotherapy in muscle-invasive bladder cancer.
    Dudek AM; van Kampen JGM; Witjes JA; Kiemeney LALM; Verhaegh GW
    Cancer Med; 2018 Jul; 7(7):3342-3350. PubMed ID: 29856124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bladder cancer.
    Sanli O; Dobruch J; Knowles MA; Burger M; Alemozaffar M; Nielsen ME; Lotan Y
    Nat Rev Dis Primers; 2017 Apr; 3():17022. PubMed ID: 28406148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involvement of Non-Coding RNAs in Chemo- and Radioresistance of Nasopharyngeal Carcinoma.
    Xiao J; He X
    Cancer Manag Res; 2021; 13():8781-8794. PubMed ID: 34849030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-coding RNAs (ncRNAs) and multidrug resistance in glioblastoma: Therapeutic challenges and opportunities.
    Subaiea GM; Syed RU; Afsar S; Alhaidan TMS; Alzammay SA; Alrashidi AA; Alrowaili SF; Alshelaly DA; Alenezi AMSRA
    Pathol Res Pract; 2024 Jan; 253():155022. PubMed ID: 38086292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A transcriptomic profile of topping responsive non-coding RNAs in tobacco roots (Nicotiana tabacum).
    Chen X; Sun S; Liu F; Shen E; Liu L; Ye C; Xiao B; Timko MP; Zhu QH; Fan L; Cao P
    BMC Genomics; 2019 Nov; 20(1):856. PubMed ID: 31726968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in the contribution of noncoding RNAs to cisplatin resistance in cervical cancer.
    Wen X; Liu S; Sheng J; Cui M
    PeerJ; 2020; 8():e9234. PubMed ID: 32523813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor expression as a predictor of chemotherapeutic resistance in muscle-invasive bladder cancer.
    Mansour AM; Abdelrahim M; Laymon M; Elsherbeeny M; Sultan M; Shokeir A; Mosbah A; Abol-Enein H; Awadalla A; Cho E; Sairam V; Park TD; Shahid M; Kim J
    BMC Urol; 2018 Nov; 18(1):100. PubMed ID: 30413194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JUND-dependent up-regulation of HMOX1 is associated with cisplatin resistance in muscle-invasive bladder cancer.
    Peng Y; Chen Y; Chen S; Wang J; Jiang C; Hou W; Xu C
    J Biochem; 2020 Jul; 168(1):73-82. PubMed ID: 32240302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic and diagnostic values of non-coding RNAs as biomarkers for breast cancer: An umbrella review and pan-cancer analysis.
    Bahramy A; Zafari N; Rajabi F; Aghakhani A; Jayedi A; Khaboushan AS; Zolbin MM; Yekaninejad MS
    Front Mol Biosci; 2023; 10():1096524. PubMed ID: 36726376
    [No Abstract]   [Full Text] [Related]  

  • 34. Targeting non-coding RNAs to overcome cancer therapy resistance.
    Chen B; Dragomir MP; Yang C; Li Q; Horst D; Calin GA
    Signal Transduct Target Ther; 2022 Apr; 7(1):121. PubMed ID: 35418578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Landscape of NcRNAs involved in drug resistance of breast cancer.
    Kang Y
    Clin Transl Oncol; 2023 Jul; 25(7):1869-1892. PubMed ID: 37067729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circ_0058063 contributes to cisplatin-resistance of bladder cancer cells by upregulating B2M through acting as RNA sponges for miR-335-5p.
    Sun M; Liu X; Zhao W; Zhang B; Deng P
    BMC Cancer; 2022 Mar; 22(1):313. PubMed ID: 35321689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Hedgehog and Hippo signaling pathways in cancer: A special focus on non-coding RNAs.
    Sharma U; Tuli HS; Uttam V; Choudhary R; Sharma B; Sharma U; Prakash H; Jain A
    Pharmacol Res; 2022 Dec; 186():106523. PubMed ID: 36377125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LncRNA MST1P2/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt1/p53 signaling.
    Chen J; Li Y; Li Z; Cao L
    J Biochem Mol Toxicol; 2020 Apr; 34(4):e22452. PubMed ID: 32052927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-coding RNAs and exosomal ncRNAs in multiple myeloma: An emphasis on molecular pathways.
    Hashemi M; Roshanzamir SM; Paskeh MDA; Karimian SS; Mahdavi MS; Kheirabad SK; Naeemi S; Taheriazam A; Salimimoghaddam S; Entezari M; Mirzaei S; Samarghandian S
    Eur J Pharmacol; 2023 Feb; 941():175380. PubMed ID: 36627099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
    Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.